The European Medicines Agency (EMA) has recommended the introduction of new safety measures for the use of Janus kinase (JAK) inhibitors to treat chronic inflammatory disorders.
The EMA’s safety committee (PRAC) has recommended that these medicines should be used as a treatment of last resort in patients aged 65 years...
